News

Eli Lilly’s weight-loss pill disappointed in a key trial, but CEO David Ricks and other insiders together bought nearly $3 ...
Eli Lilly and Company faces valuation pressure after disappointing Orforglipron results. Click here to read an analysis of ...
Lilly's weight-loss medications Mounjaro and Zepbound are gaining market share on Novo's Wegovy and Ozempic, but investors ...
In a Phase 3 trial, drugmaker Eli Lilly and Company said it's oral GLP-1 pill showed similar results to injectable weight ...
The company said it planned to seek Food and Drug Administration approval for the drug, orforglipron, before the end of the ...
Eli Lilly on Thursday released data for its daily obesity pill, orforglipron, which found the medication helped obese or ...
South Korea’s pharma industry has a valuable pool of promising drugs, but China still leads the way in out-licensing deals.
Eli Lilly and Company (NYSE: LLY) is one of the Good Stocks to Invest in Now. On August 7, Eli Lilly and Company (NYSE:LLY) ...